On Nov. 9, 2021, Inovio Pharma announced that the U.S. Food and Drug Administration provided authorization to proceed for INOVIO’s INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

The FDA lifted the partial clinical hold following the FDA’s review of additional non-clinical, clinical, and device information provided by INOVIO.